These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14505916)

  • 1. Phase II safety and immunogenicity study of type F botulinum toxoid in adult volunteers.
    Edelman R; Wasserman SS; Bodison SA; Perry JG; O'Donnoghue M; DeTolla LJ
    Vaccine; 2003 Oct; 21(27-30):4335-47. PubMed ID: 14505916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid.
    Pittman PR; Hack D; Mangiafico J; Gibbs P; McKee KT; Friedlander AM; Sjogren MH
    Vaccine; 2002 May; 20(16):2107-15. PubMed ID: 11972980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa).
    Dhillon S
    BioDrugs; 2010 Oct; 24(5):299-302. PubMed ID: 20795752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine.
    Faingezicht I; Avila-Aguerro ML; Cervantes Y; Fourneau M; Clemens SA
    Rev Panam Salud Publica; 2002 Oct; 12(4):247-57. PubMed ID: 12431356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults.
    Sheldon E; Kitchin N; Peng Y; Eiden J; Gruber W; Johnson E; Jansen KU; Pride MW; Pedneault L
    Vaccine; 2016 Apr; 34(18):2082-91. PubMed ID: 26993331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan.
    Torii Y; Sugimoto N; Kohda T; Kozaki S; Morokuma K; Horikawa Y; Ginnaga A; Yamamoto A; Takahashi M
    Jpn J Infect Dis; 2017 Jul; 70(4):423-429. PubMed ID: 28250257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system.
    Thoelen S; Van Damme P; Mathei C; Leroux-Roels G; Desombere I; Safary A; Vandepapeliere P; Slaoui M; Meheus A
    Vaccine; 1998 Apr; 16(7):708-14. PubMed ID: 9562690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a fully liquid aluminum phosphate adjuvanted Haemophilus influenzae type b PRP-CRM197-conjugate vaccine in healthy Japanese children: A phase III, randomized, observer-blind, multicenter, parallel-group study.
    Togashi T; Mitsuya N; Kogawara O; Sumino S; Takanami Y; Sugizaki K
    Vaccine; 2016 Aug; 34(38):4635-4641. PubMed ID: 27265451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
    Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
    Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults.
    Kotloff KL; Wasserman SS; Losonsky GA; Thomas W; Nichols R; Edelman R; Bridwell M; Monath TP
    Infect Immun; 2001 Feb; 69(2):988-95. PubMed ID: 11159994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults.
    Aguilar-Betancourt A; González-Delgado CA; Cinza-Estévez Z; Martínez-Cabrera J; Véliz-Ríos G; Alemán-Zaldívar R; Alonso-Martínez MI; Lago-Baños M; Puble-Alvarez N; Delahanty-Fernandez A; Juvier-Madrazo AI; Ortega-León D; Olivera-Ruano L; Correa-Fernández A; Abreu-Reyes D; Soto-Mestre E; Pérez-Pérez MV; Figueroa-Baile N; Pérez LH; Rodríguez-Silva A; Martínez-Díaz E; Guillén-Nieto GE; Muzio-González VL
    Hum Vaccin; 2008; 4(1):54-9. PubMed ID: 18441530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
    Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial.
    de Bruyn G; Saleh J; Workman D; Pollak R; Elinoff V; Fraser NJ; Lefebvre G; Martens M; Mills RE; Nathan R; Trevino M; van Cleeff M; Foglia G; Ozol-Godfrey A; Patel DM; Pietrobon PJ; Gesser R;
    Vaccine; 2016 Apr; 34(19):2170-8. PubMed ID: 27013431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U; ; ; Sänger R; Jacquet JM; Schuerman L
    Vaccine; 2007 Jan; 25(6):1055-63. PubMed ID: 17049692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L
    Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
    Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
    Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.